MapLight Therapeutics, part of the 2025 biotech IPO class, has "separated" from the CFO who took it public. Here's what we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results